Provention Bio, Inc. (PRVB) News
Filter PRVB News Items
PRVB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRVB News Highlights
- For PRVB, its 30 day story count is now at 5.
- Over the past 27 days, the trend for PRVB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PRVB are BIO, ACT and AIM.
Latest PRVB News From Around the Web
Below are the latest news stories about PROVENTION BIO INC that investors may wish to consider to help them evaluate PRVB as an investment opportunity.
Sanofi/Provention: innovative diabetes drug is a good fitUS diabetes drugmaker Provention Bio is a case in point. Sanofi has bought it for $2.9bn in cash, more than three times its undisturbed price, in a deal that closed last week. The deal is a good fit for Sanofi, even though boss Paul Hudson pulled back from diabetes research in 2019. |
Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit... |
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineProvention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationSanofi SA (NASDAQ: SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC) regarding the acquisition of Provention Bio Inc (NASDAQ: PRVB). Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion. The agency, it added, needed more time to look at the deal and “information recently provided to them,” Sanofi said |
Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Provention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their EstimatesProvention Bio, Inc. ( NASDAQ:PRVB ) just released its latest full-year results and things are looking bullish... |
Is Sanofi Stock a Buy Now?French pharmaceutical giant Sanofi (NASDAQ: SNY) has long been a leader in the market for insulin. First, Sanofi was forced to decrease the price of its most prescribed insulin product after its only two real competitors in this area did something similar. Second, Sanofi announced the acquisition of Provention Bio, a biotech focusing on developing medicines to delay or prevent the onset of autoimmune diseases, such as Type 1a diabetes. |
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call TranscriptMacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Good afternoon. We will begin the MacroGenics 2022 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment. At this point, I will turn the call over to Jim Karrels, Senior Vice President, Chief Financial Officer of MacroGenics. Jim Karrels: […] |
Why Provention Bio Stock Skyrocketed 256% This WeekProvention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. |
Q4 2022 MacroGenics Inc Earnings CallQ4 2022 MacroGenics Inc Earnings Call |